注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Aethlon Medical Inc (Aethlon)是一家生物技术公司。该公司专注于开发诊断和治疗生命和器官威胁疾病的产品。它参与开发血液纯化器,一种用于传染病和癌症的治疗性血液过滤系统。该公司通过两个部门运营:Aethlon和ESI。Aethlon部门代表其治疗业务活动。ESI部门代表其诊断业务。在癌症中,Hemopurifier被设计用来消除循环肿瘤来源的外泌体,这些外泌体会促进免疫抑制,播下转移扩散的种子。该公司正在对晚期和转移性头颈部癌症患者进行临床试验。它专注于用检查点抑制剂治疗实体肿瘤的治疗。血液纯化剂已被用于治疗感染人类免疫缺陷病毒(HIV)、丙型肝炎病毒(HCV)和埃博拉病毒的个人。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Edward G. Broenniman | 86 | 1999 | Independent Chairman of the Board |
Geert Schmid-Schönbein | - | - | Member of Sepsis & Inflammation Advisory Board |
Stephen Z. Fadem | - | - | Member of Extracorporeal Therapy Advisory Board |
Nicolas Gikakis | 57 | 2023 | Independent Director |
Nathan W. Levin | - | - | Member of Extracorporeal Therapy Advisory Board |
Larry D. Cowgill | - | - | Member of Sepsis & Inflammation Advisory Board |
Gregory T. A. Kovacs | - | - | Member of Extracorporeal Therapy Advisory Board |
Irshad H. Chaudry | - | - | Member of Sepsis & Inflammation Advisory Board |
David M. Ward | - | - | Member of Extracorporeal Therapy Advisory Board |
Claudio Ronco | - | - | Member of Extracorporeal Therapy Advisory Board |
John A. Kellum | - | - | Member of Extracorporeal Therapy Advisory Board |
Chetan S. Shah | 54 | 2013 | Independent Director |
Angela Rossetti | 70 | 2022 | Independent Director |
Charles J. Fisher | 76 | 2017 | Member of Extracorporeal Therapy Advisory Board |
James B. Frakes | 67 | 2008 | Interim CEO, CFO, Secretary & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核